

Open access • Posted Content • DOI:10.1101/2021.10.01.462764

Non-conserved metabolic regulation by LKB1 distinguishes human and mouse lung adenocarcinoma — Source link 🗹

Benjamin D. Stein, John Ferrarone, Eric E Gardner, Jae Won Chang ...+14 more authors


Institutions: Cornell University, University of Chicago, Salk Institute for Biological Studies, Beth Israel Deaconess Medical Center

Published on: 02 Oct 2021 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: KRAS, Mutation, Kinase, Flux (metabolism) and Mutant

Related papers:

- Crosstalk of LKB1-regulated and PTEN-regulated signals in liver morphogenesis and tumor development in mice
- Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
- Mutant TP53 Posttranslational Modifications: Challenges and Opportunities
- Polymorphism of p53 in cancer prognosis
- Reduced HRASG12V-Driven Tumorigenesis of Cell Lines Expressing KRASC118S



Non-conserved metabolic regulation by LKB1 distinguishes human and mouse lung adenocarcinoma

3 Benjamin D. Stein^{1,11*}, John R. Ferrarone^{1,11}, Eric E. Gardner¹, Jae Won Chang^{2,6}, David Wu¹, Qiuying 4 Chen³, Pablo E. Hollstein^{4,7}, Min Yuan⁵, Roger J. Liang^{1,8}, John S. Coukos², Miriam Sindelar^{3,9}, Bryan Ngo^{1,10}, Steven S. Gross³, Reuben J. Shaw⁴, John M. Asara⁵, Raymond E. Moellering², Harold Varmus^{1*}, 7 Lewis C. Cantley^{1*}

9 ¹Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA. ²Department of 10 Chemistry, University of Chicago, Chicago, IL 60637, USA. ³Department of Pharmacology, Weill Cornell Medicine, 11 New York, NY 10065, USA. ⁴Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, 12 CA 92037, USA. ⁵Mass Spectrometry Core, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. 13 ⁶Current address: Emory University, Atlanta, GA 30322, USA. ⁷Current address: Amgen, Thousand Oaks, CA 07004, 14 USA. ⁸Current address: University of Texas – Southwestern, Dallas, TX 75390, USA. ⁹Current address: Washington 15 University in St. Louis, Saint Louis, MO 63130, USA. ¹⁰Current address: Memorial Sloan Kettering Cancer Center, 16 New York, NY 10021, USA. ¹¹These authors contributed equally; *correspondence e-mail: bds2005@med.cornell.edu; 17 varmus@med.cornell.edu; lcantley@med.cornell.edu

18 19 KRAS is the most frequently mutated oncogene in human lung adenocarcinomas (hLUAD) and 20 activating mutations in KRAS frequently co-occur with loss-of-function mutations in the tumor 21 suppressor genes, TP53 or STK11/LKB1. However, mutation of all three genes is rarely observed in 22 hLUAD, even though engineered mutations of all three genes produces a highly aggressive lung 23 adenocarcinoma in mice (mLUAD). Here we provide an explanation of this difference between 24 hLUAD and mLUAD by uncovering an evolutionary divergence in regulation of the glycolytic 25 enzyme triosephosphate isomerase (TPI1). Using KRAS/TP53 mutant hLUAD cell lines, we show 26 that TPI1 enzymatic activity can be altered via phosphorylation at Ser21 by the Salt Inducible 27 Kinases (SIKs) in an LKB1-dependent manner; this allows modulation of glycolytic flux between 28 completion of glycolysis and production of glycerol lipids. This metabolic flexibility appears to be 29 critical in rapidly growing cells with KRAS and TP53 mutations, explaining why loss of LKB1 creates a metabolic liability in these tumors. In mice, the amino acid at position 21 of TPI1 is a Cys residue 30 31 which can be oxidized to alter TPI1 activity, allowing regulation of glycolytic flux balance without a 32 need for SIK kinases or LKB1. Our findings reveal an unexpected role for TPI1 in metabolic 33 reprogramming and suggest that LKB1 and SIK family kinases are potential targets for treating 34 KRAS/TP53 mutant hLUAD. Our data also provide a cautionary example of the limits of genetically 35 engineered murine models as tools to study human diseases such as cancers.

36 37 Lung cancer remains the most common cause of cancer mortality in the United States and worldwide, due 38 to high incidence coupled with poor response to standard-of-care therapies in most patients.¹ Metabolic 39 reprogramming is a cancer hallmark, required to support tumorigenesis in diverse environments.^{2,3} Despite 40 improvements in our understanding of metabolic discrepancies between normal and oncogenic tissues, 41 accurately modeling and exploiting these differences for therapeutic intervention has achieved only marginal 42 success.

43 44 Inherent differences between humans and mice may have significant effects on tumor development 45 through divergent mechanisms of response to the oxidative environment and to metabolic determinants.⁴ 46 The nature and extent of such differences are unknown, but their mechanisms may illuminate unidentified 47 molecular targets for therapy. Therefore, we sought to identify differences between human and mouse lung 48 adenocarcinomas (hLUAD and mLUAD) with the most common genotype, mutated KRAS and TP53 (KP-49 mutant) and determine the effects of loss of the tumor suppressor, LKB1, on metabolic regulation and the 50 growth of such tumors.

51

1

2

5 6

- 52
- 53

54 **Co-occurrence of** *KRAS*, *TP53* and *LKB1* mutations differentially affects growth of human and 55 **mouse LUADs**

56 57 We used the TCGA PanCancer Atlas to determine the frequency of co-occurrence of mutations in the three 58 most commonly mutated genes in hLUAD - KRAS, TP53 and LKB1 - and found that only 8 of 511 tumors 59 carried mutations in all three genes (Figure 1A). A Fisher's Exact test showed that the co-occurrence of 60 LKB1 and TP53 mutations in hLUADs with a KRAS mutation was less frequent than expected by chance, 61 based on the overall frequency of mutations in these three genes, with an odds ratio of 0.35 and a P-value 62 of 0.01 (Figure 1B). No similar reduction was observed in the co-mutation of TP53 and LKB1 in the 63 absence of KRAS mutations (odds ratio = 0.95; p-value of 0.87) (Figure 1B). A second data set from 64 Memorial Sloan Kettering Cancer Center consisting of 1,357 lung cancer patients revealed similar 65 exclusivity of triple mutant cases (Figure S1A and S1B).⁵

66

67 While mutations in KRAS, TP53 and LKB1 together are rare in hLUAD, previous studies have shown 68 that genetically engineered mouse models (GEMMs) harboring conditional mutations in all three genes 69 develop mLUAD that is more aggressive and more likely to metastasize than mLUAD with only two of these genes mutated.⁶⁻⁹ To investigate this discrepancy between LUAD in human patients and mouse models, we 70 first generated isogenic clones of human KP cell lines with and without LKB1 deficiency and compared them 71 to existing GEMM-derived mouse tumor lines with parallel genotypes.⁸ The human KP lines engrafted and 72 73 formed tumors in vivo, whereas isogenic lines in which LKB1 was deleted (KPL) did not (Figure 1C). 74 Furthermore, human KP lines readily formed spheroids in organotypic culture, but KPL lines did not (Figure S1C). In contrast, GEMM-derived KP and KPL lines both formed tumors in vivo and spheroids in vitro 75 76 (Figures 1D and S1D). 77

78 To determine whether these observations were attributable to LKB1 kinase activity, wildtype or 79 kinase-inactive (K78I) LKB1 were re-expressed in isogenic KPL hLUAD lines derived from two human KP 80 lines. We first verified that wildtype LKB1 restored the activity of AMP-activated protein kinase (AMPK), a 81 known substrate of LKB1, under conditions of energy stress. Glucose restriction caused LKB1-dependent 82 phosphorylation of AMPK at Thr172 and of its downstream substrates (Acetyl CoA Carboxylase (ACC) at 83 Ser79, Raptor at Ser792, and Unc-51 Like autophagy activating Kinase 1 (ULK1) at Ser555) (Figure 1E 84 and Figure S1E). Expression of wildtype (WT), but not kinase-inactive (KI), LKB1 rescued growth of the 85 xenografts in immunodeficient mice, suggesting that LKB1 kinase activity is required to support tumor 86 formation by human KP LUAD cells (Figure 1F). 87

88 **Phosphorylation of human TPI1 is LKB1-dependent**

89 90 Since LKB1 phosphorylates and activates a family of AMPK-related Ser/Thr protein kinases (AMPKRs) 91 involved in regulating various metabolic and stress response pathways, we used comprehensive 92 guantitative phospho-proteomics under glucose-limited conditions to assess differences in protein 93 phosphorylation between KP and KPL isogenic human lines. Phosphorylation of Ser21 on the glycolytic 94 enzyme Triosephosphate Isomerase (TPI1) was one of the most significantly down-regulated 95 phosphorylation events observed when comparing KPL to KP (Figure 2A, S2A and S2B). As expected, we 96 also observed reduced phosphorylation of Ser108 in the beta subunits of AMPK: PRKAB1, and PRKAB2, 97 each required for enzymatic activity (Figures S2B). In contrast, using the same experimental design with 98 tumor-derived mouse cell lines, we did not detect phosphorylation of Tpi1 in cells with either KP or KPL 99 genotypes (Figure S2C).

100

To assess if restoration of LKB1 kinase activity re-established phosphorylation of TPI1 during metabolic stress, we used quantitative proteomics and phospho-proteomics to analyze human KPL cells expressing WT or KI LKB1 in parallel with KP and KPL cells under glucose-limited conditions. Ser21 phosphorylation (p-Ser21) on TPI1 was again one of the most significantly reduced phosphorylation sites when KPL cells and KPL cells expressing KI LKB1 were compared with KP cells and KPL cells expressing WT LKB1 (**Figure 2B**). Furthermore, quantification of phosphopeptide ion intensities within individual genotypes confirmed restoration of p-Ser21 levels in human KPL lines expressing WT, but not KI LKB1
 (Figure S2D), without significant variation in the abundance of TPI1 protein.

109

110 Phosphorylation of TPI1 regulates triose phosphate levels

111 112 To examine the possibility that loss of regulation of TPI1 in hLUAD might explain selection against the KPL 113 genotype, we studied the metabolic consequences of LKB1 deficiency. It is known that TPI1 controls the 114 interconversion of the triose phosphates, dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-115 phosphate (GAP), both of which are generated from the upstream glycolytic intermediate fructose-1.6-116 bisphosphate (1,6-FBP) by aldolase. This conversion in carbon metabolism lies at a critical bifurcation 117 point: one product, GAP, is used for glycolysis and energy homeostasis, whereas the other, DHAP, is used 118 for lipid synthesis, cellular growth, and has recently been shown to activate the mammalian Target of Rapamycin protein kinase (mTOR).¹⁰ Additionally, previous studies have shown that increased oxidative 119 burden due to KRAS and/or TP53 mutations cause metabolic flux to primarily flow through the oxidative 120 121 Pentose Phosphate Pathway (oxPPP) to increase reductive potential and restore redox balance to overcome this liability.¹¹⁻¹³ 122

123

124 We next assessed the influence of LKB1-dependent phosphorylation on TPI1 activity by measuring 125 the pools of GAP and DHAP in KP and KPL hLUAD cell lines. Due to the inherent instability and complex 126 chromatographic separation of the triose phosphates, we used in situ chemical-trapping metabolomics with 127 hydroxylamine labeling of live cells under normal and glucose limited conditions prior to lysis to create stable adducts and measured them (Figure 2C and S2E).¹⁴ These analyses confirmed relative elevation of 128 129 DHAP in KPL lines, further suggesting that TPI1 phosphorylation limited DHAP accumulation to maintain 130 GAP for glycolysis, crucial under glucose-limited conditions (Figure 2D). Additionally, a parallel analysis 131 including KPL cell lines expressing WT and KI LKB1 with the same method revealed that levels of GAP and 132 DHAP in WT LKB1 wildtype lines more accurately recapitulated endogenous levels in KP human cells, while 133 DHAP remained elevated in the LKB1-KI cells (Figure S2F). Furthermore, steady-state analysis revealed 134 that human KPL cells had a significant increase in glycerol-3-phosphate, the next metabolic intermediate in 135 the lipid and triglyceride synthesis pathway under normal and low glucose conditions (Figure 2E). 136 Collectively, the observed changes in metabolites and phosphorylation of human TPI1 suggested that LKB1 137 regulates distribution of alvcolvtic metabolites via the triose phosphates through a regulatory 138 phosphorylation site in TPI1. 139

140 Non-conserved amino acid sequence of TPI1 requires LKB1 to regulate its multimeric state in 141 human but not mouse LUAD

141 142

143 To determine whether differences between LKB1 loss in human and mouse LUAD cells could be explained 144 by differences in regulation of TPI1/Tpi1, we explored the evolutionary conservation of the primary amino 145 acid sequence surrounding position 21 of this enzyme. Ser21 and the surrounding residues are conserved 146 in most mammals and many other metazoan organisms, including yeast. However, in mouse and rat Tpi1, 147 Ser21 has been replaced by a cysteine (Figure 3A). In a published crystal structure of human TPI1, the 148 hydroxyl mojety of Ser21 is located at a region of subunit:subunit interactions, stabilizing the homodimer. 149 Notably, the nearby residues Arg18 and Lys19 form inter-subunit electrostatic interactions predicted to 150 further stabilize the highly active homodimeric state. This structure raises the possibility that 151 phosphorylation of Ser21 could produce intra-subunit charge interactions with Arg18 and/or Lys19, 152 interfering with the ability of these amino acids to confer stability to the dimer, thereby altering enzymatic 153 activity (Figure 3B).¹⁵ Since the sulfur atom of Cys21 in rodent Tpi1 could be oxidized to sulfinic or sulfonic 154 acid, mimicking phosphorylation of Ser21, it is possible that rodents have a mechanistic alternative to 155 phospho-dependent regulation of TPI1 activity. This could explain differences in the response to loss of 156 LKB1 in mouse and human tumors, circumventing the requirement for LKB1 activity in murine tumors. 157

Based on the structural features of human and mouse TPI1/Tpi1, we next asked whether the loss of LKB1 kinase activity, which prevents phosphorylation of human TPI1 at Ser21, would differentially affect the dimerization and activity of this enzyme in cells from the two species. We used native gel electrophoresis 161 (BN-PAGE) and western blotting to determine the proportions of monomeric and dimeric TPI1 in extracts of 162 two human KP cell lines, in the presence and absence of LKB1, when cells are grown under normal glucose 163 conditions (Figure 3C). Loss of LKB1 promoted the dimeric (more slowly migrating) form of the human 164 protein; conversely, cell lines expressing LKB1 had increased monomeric (more rapidly migrating) TPI1 (Figure 3C). Thermal Proteome Profiling (TPP) was also used to measure the thermal stability of TPI1 165 proteoforms.^{16,17} The Δ Tm (measured at 0.5 fraction denatured) of the phosphorylated variant was 5.8°C 166 167 lower than that of unmodified TPI1, further supporting the prediction that phosphorylation of Ser21 disrupts 168 TPI1 dimerization (Figure 3D).

169

In contrast, we observed no changes in the ratio of the monomeric and dimeric forms of mouse Tpi1
in KP versus KPL mLUAD cell lines at high (11.1 mM) or low (0.5 mM) glucose concentrations (Figure 3E).
However, acute treatment of the mouse lines with the oxidant peroxide caused a dramatic shift towards the
rapidly migrating (monomeric) form of Tpi1 in low glucose medium, regardless of Lkb1 status (Figure 3E).
Additionally, peroxide treatment caused a similar shift towards monomeric Tpi1 under high (11.1 mM)
glucose conditions in KPL, but not KP mouse cells (Figure 3E), consistent with earlier reports that loss of
Lkb1 increases basal oxidative stress.¹⁸⁻²¹

177

To further explore the functional significance of the amino acid difference at position 21 of TPI1 and 178 Tpi1 and its effect on homodimer formation, we created an allelic panel of FLAG-HA-tagged TPI1 variants 179 180 expressed as transgenes in human KP cells following deletion of endogenous TPI1. We observed that 181 replacement of Serine with Alanine (S21A) increased recovery of both the transgenic and remaining 182 endogenous TPI1 by immunoprecipitation, implying that an inability to phosphorylate position 21 of TPI1 183 stabilized the TPI1 dimer. In contrast, the phospho-mimetic S21D mutant form of TPI1 or a mutant in which 184 Ser21 is replaced by an oxidizable cysteine (S21C) significantly reduced co-immunoprecipitation of the 185 remaining endogenous TPI1 (Figure 3F). These findings were further confirmed when TPI1 variants from 186 the allelic panel were analyzed by BN-PAGE. Wildtype transgenic human TPI1 was found in both the 187 dimeric and monomeric states, but the S21A mutant was detected solely in the dimeric state, and the S21C 188 variant was mostly monomeric (Figure 3G). Collectively, these findings support the conclusion that 189 phosphorylation of human TPI1 or oxidation of murine Tpi1 destabilizes its dimeric form, providing a 190 structural mechanism by which TPI1/Tpi1 activity can be regulated in response to LKB1-dependent 191 phosphorylation or by oxidative stress.

192

193 LKB1-activated members of the Salt Inducible Kinase family phosphorylate human TPI1 194

We next sought to determine whether human TPI1 is phosphorylated directly by LKB1 or by one of the downstream LKB1-dependent Ser/Thr protein kinases of the AMPKR family; these kinases are known to mediate responses to various metabolic stresses, all of which require phosphorylation by LKB1 for activity (**Figure 4A**).²²⁻²⁴

199

200 To determine whether AMPKR kinases are directly responsible for TPI1 phosphorylation 201 downstream of LKB1, we monitored phosphorylation of Ser21 in TPI1 in a panel of human KRAS; LKB1-202 mutant cell lines in which sub-families of the AMPKR kinases have been genetically eliminated, after 203 restoring stable expression of WT LKB1 from a transgene (Figure 4B).⁷ Restoration of LKB1 increased the 204 phosphorylation of Ser21 in TPI1, consistent with results in Figure 2B and S2D, and deletion of the Salt 205 Inducible Kinase (SIK) subfamily significantly reduced Ser21 phosphorylation (Figure 4B). Deletion of other 206 AMPKR super-family members [the Microtubule Affinity Regulating Kinases (MARKs), the NUAK Family 207 Kinases (NUAKs), the Brain-Specific Serine/Threonine-Protein Kinases (BRSKs), the catalytic subunits of 208 AMPK, and SNF Related Kinase (SNRK)] did not have significant effects on Ser21 phosphorylation of TPI1. 209 Furthermore, by analyzing specific combinations of deletions of SIK family members, we found that SIK1 210 and SIK3 together made the greatest contribution to phosphorylation of Ser21 in TPI1 (Figure S3A). 211

In agreement with the concept that the SIK sub-family of protein kinases drive phosphorylation of Ser21 in TPI1, phosphorylation of Ser551 in SIK3, known to regulate activity through altering molecular association, was one of the most significantly down-regulated phosphorylation sites in the LKB1-deleted, KP-mutant hLUAD cell lines (Figure S2A).^{25,26} Additionally, phosphorylation of the regulatory sites in a SIKfamily substrate, CREB Regulated Transcription Coactivator 3 (CRTC3), was also down-regulated in KPL versus KP human lines (Figures S2A and S2B). Furthermore, we found that the amount of *SIK1* mRNA was significantly increased upon inactivation of *LKB1* in multiple human KP lines, suggesting that a signaling network might increase transcription of *SIK1* via a feedback mechanism to recover SIK activity after loss of LKB1 (**Figure S3B**).

We next asked if SIK family kinases were responsible for phosphorylation of TPI1 in human KP 222 223 lines that express LKB1 from the endogenous LKB1 locus. We generated a series of cell lines deficient in 224 members of the SIK gene family, including two SIK1/2/3 triple knockout lines (SIK TKO). Analysis of this 225 series of cell lines by western blot confirmed significant deletion of all SIK family members in the SIK TKO 226 lines (Figure S3C). A quantitative proteomic analysis of differences between SIK WT and SIK TKO cells 227 revealed that KRAS was among the most significantly down-regulated proteins (Figure 4C). This 228 observation is consistent with SIK family enzymes being critical for cell growth when mutant KRAS is 229 present and TP53 is mutated. Measurement of the TPI1 p-Ser21 tryptic peptide from cells with various 230 combinations of SIK1, SIK2 and SIK3 deletions argues that each of these kinases contribute to 231 phosphorylation of TPI1 at Ser21 in human KP cells (Figure 4D). 232

233 Taken together, these results indicate that in the KP hLUAD cell lines investigated, the SIK family of 234 LKB1-regulated protein kinases appear to dominate the phosphorylation of Ser21 in TPI1, although deletion 235 of all three SIK family members did not eliminate phosphorylation at this site, suggesting that other LKB1-236 regulated protein kinase may also contribute to TPI1 phosphorylation or compensate for loss of the SIK 237 kinases. Our results suggest that an LKB1 inhibitor might be an effective therapy for KP mutant hLUADs, 238 though there are likely to be significant toxicities associated with the inhibition of LKB1. An alternative, 239 potentially less toxic therapy would inhibit a sub-group of LKB1-regulated protein kinases, including the SIK 240 family kinases, in KRAS; TP53 human lung adenocarcinoma. 241

243 **Discussion**

244

242

221

Although much progress has been made using GEMMs to decipher mechanisms of tumor initiation and progression, comparisons of human and mouse tumors often lead to conflicting observations.²⁷ In particular, accurately recapitulating the tumor metabolic environment remains a significant challenge, but an important one, since discrepancies between mouse and human tumors are likely to have implications in development of novel therapeutic agents.²⁸ Here we provide a mechanistic explanation for why the loss of LKB1 in hLUADs driven by *KRAS* and *TP53* mutations is a rare event that appears to be selected against in human tumors, but not in mouse tumors, where the loss of Lkb1 enhances tumorigenesis and metastasis.

252 253 Several recent reports have implicated the SIK kinases as effectors of LKB1-mediated tumor 254 suppression in Kras- and Kras; Tp53-mutant mLUAD; however similar findings have not been reported in 255 hLUADs.^{7,29} Here we find that this discrepancy may be due, at least in part, to a single amino acid 256 difference between rodent and other metazoan versions of the alvcolvtic enzyme TPI1. In turn, that 257 difference can influence subsequent metabolic events, that determine the flow of glucose-derived tri-carbon 258 substrates into pathways for glycolysis or lipid synthesis. In humans, the abundance of the products of TPI1 259 is governed by the LKB1-SIK-TPI1 signaling axis that we have elucidated in this manuscript. In rodents, the 260 substitution of an oxidizable cysteine for a phosphorylatable serine at residue 21 of Tpi1 enables direct 261 redox regulation, circumventing the requirement for regulation by LKB1-SIK-mediated phosphorylation. Our 262 biochemical, proteomic, and metabolomic data support the conclusion that phosphorylation of TPI1 in 263 hLUAD regulates the biophysical distribution of monomeric and dimeric forms, altering enzymatic activity and in turn triose phosphate pools. This reduces the conversion of GAP to DHAP, an energetically downhill 264 265 reaction, and thereby shifts the balance away from glycerol lipid production and towards alternate metabolic 266 pathways, including glycolysis and the TCA cycle. Regulation of metabolites at this central point in the 267 glycolytic pathway could help to overcome metabolic stresses experienced during tumorigenesis and to 268 improve the efficiency of energy production. In addition, this regulation allows rapidly growing cells to

balance pathways for lipid synthesis versus serine/glycine synthesis. Collectively, these metabolic
differences could strongly influence a wide range of pro-tumorigenic processes and have significant effects
on tumor cell phenotype, all of which warrant future study. Additional features of these phenomena - such
as how specific *KRAS* and *TP53* mutations influence this phenotype and their contributions to the response
to metabolic and oxidative stresses - have yet to be deciphered.

Knowledge of the differences in human and mouse TPI1/Tpi1 may not only explain the different consequences of loss of LKB1 in human and mouse LUADs but may also help to design next-generation mouse models in which the mechanisms of metabolic regulation of human cancers are more accurately replicated. Furthermore, the research reported here suggests that selective inhibitors of LKB1 or of SIK family protein kinases could be effective in treating human Kras/TP53 mutant lung cancers or other cancers with KRAS/TP53 mutations. But our work also raises the cautionary note that preclinical trials with such inhibitors would likely fail in currently available GEMMs with Kras and Tp53 mutations.

282

274

Finally, the observations reported here also reveal new ways for LKB1 to regulate metabolism, beyond its known capacity to respond to cellular energy levels through activation of AMPK.³⁰ While enzymes such as hexokinase, pyruvate kinase and phosphofructokinase have been intensely studied in regard to phosphorylation-dependent regulation in cancers, TPI1 has not been considered a likely site for cancer-dependent regulation of metabolic flux. Additional research is needed to understand how critical this regulation is to other types of human cancers and whether this knowledge can lead to new cancer therapies across multiple organ types and multiple mutational backgrounds.

290 291

292 Data Availability

All derived MS/MS data will be deposited on MASSive and ProteomeXchange.

294

295 Supplemental Information

296 Supplemental Information includes 3 supplemental figures.

297

298 Acknowledgements

299 We thank Kwok-Kin Wong for kindly providing GEMM derived LUAD cell-lines; 634T and Lkb1-t2. This 300 work was supported, in part, by NIH grants; P01CA120964 (to L.C.C., R.J.S. and J.M.A.), R35CA197588 (to 301 L.C.C.), R35-CA220538 (to R.J.S.), R01-DK080425 (to R.J.S.), R01AR076029 (to Q.C.) and R21ES032347 302 (to Q.C.); NSF-CAREER CHE-1945442 (to R.E.M.) and the Alfred P. Sloan Foundation FG-2020-12839 (to 303 R.E.M.). H.E.V. is the Lewis Thomas University Professor at Cornell University. J.R.F. is the Lee 304 Cooperman Physician-Scientist of the Damon Runyon Cancer Research Foundation (DRG 18-18). E.E.G. 305 is the Kenneth G. and Elaine A. Langone Fellow of the Damon Runyon Cancer Research Foundation 306 (DRG-2343-18). B.N. is supported by a National Cancer Institute (NCI) of the National Institutes of Health 307 (NIH) F99/K00 Career Transition Fellowship (F99CA234950).

308309 Author Contributions

310 B.D.S., H.E.V., and L.C.C. conceived of and designed the study. B.D.S. guided and performed most 311 experiments, performed all proteomics and biochemical experiments, metabolomics experiments and all 312 computational analyses. J.R.F. performed experiments and analyzed clinical data. E.E.G., D.W. and B.N. 313 assisted in xenograft studies in Figures 1C, 1D and 1F. E.E.G. performed 3D Matrigel experiments in 314 Figure S1C. J.W.C., J.S.C. and R.E.M. performed and analyzed chemical trapping metabolomics data in 315 Figure 2D. M.Y. and J.M.A. performed metabolomics analyses in Figures 2E. Q.C., M.S. and S.S.G. 316 analyzed metabolomics experiments. P.E.H. and R.J.S. provided cell-lines and lysates utilized for 317 proteomics in Figure 4B and S4A. R.J.L. performed experiments. B.D.S. wrote the manuscript, which was 318 reviewed by all authors. H.E.V. and L.C.C. supervised the study.

- 319
- 320
- 321

322 Competing Interests

L.C.C. is a co-founder and member of the SAB and holds equity in Faeth Therapeutics, Volastra
 Therapeutics and Larkspur Therapeutics. He is also a co-founder, former member of the SAB and BOD
 and holds equity in Agios Pharmaceuticals. H.E.V. is a member of the SABs of Volastra, Dragonfly
 Therapeutics, and Surrozen. These companies are developing novel therapies for cancer. L.C.C.'s
 laboratory has previously received some financial support from Petra Pharmaceuticals. None of these
 companies are developing drugs related to the research in this paper. All other authors declare no
 competing interests.

376 Figure Legends

377

Figure 1. Co-occurrence of *KRAS*, *TP53* and *LKB1* mutations differentially affects growth of human and mouse LUADs.

380 (A) The Cancer Genome Atlas PanCancer Atlas oncoprint of co-occurrence of KRAS, TP53 and LKB1 in 381 human lung adenocarcinoma patients. (B) Fisher's exact test of statistical likelihood of co-occurrence of 382 LKB1 and TP53 mutations in a KRAS mutant or wildtype background respectively. (C) Graph of mean (+/-383 s.e.m.) tumor volumes of sub-cutaneous flank injections of H358 (KRAS:TP53) isogenic clones expressing 384 a non-targeting (sqNT1.4 and sqNT1.6) or LKB1-specific (sqLKB1-2.1 and sqLKB13.2) guide Cas9 and 385 RNA. 1×10^6 cells implanted in right hind flank (n = 10 per cohort). (D) Mean (-/+ s.e.m.) volumes of 386 mouse 634T (KP) and Lkb1-t2 (KPL) lung adenocarcinoma allograft tumors. 1 x 10⁴ cells implanted in right 387 hind flank (n = 10 per cohort). (E) Western blot analysis of H358 (KRAS; TP53) isogenic clones (KP: 388 sgNT1.4 and sgNT1.6; KPL: sgLKB1-2.1 and sgLKB1-3.2) and KPL lines with additional transgenic 389 expression of guide RNA resistant LKB1 wildtype (WT) (sgLKB1-2.1 + LKB1 WT and sgLKB1-3.2 + LKB1 390 WT) or LKB1 kinase inactive (KI) (sqLKB1-2.1 + LKB1 KI and sqLKB1-3.2 LKB1 KI) and treated with 11.1 391 mM or 0.5 mM glucose for 6 hours as indicated. Restoration of AMPK signaling in LKB1 WT lines in 392 response to 0.5 mM glucose validated by blotting for P-AMPK Thr172 and downstream substrates (P-ACC 393 S79. P-ULK1 S555. P-Raptor S792). Similar results observed in three independent experiments and in an 394 additional KRAS; TP53 cell line, H2009 (Figure S1E). (F) Graph of mean (-/+ s.e.m.) tumor volumes of sub-395 cutaneous flank injections of H358 (KRAS;TP53) isogenic clones with transgenic expression of an empty 396 vector (KO) or guide RNA resistant LKB1 wildtype (LKB1 WT) or LKB1 kinase inactive (LKB1 KI). 1 x 10⁶ 397 cells implanted in right hind flank (n = 10 per cohort).

398

399 Figure 2. Phosphorylation of human TPI1 is LKB1-dependent and regulates triose phosphate levels. 400 (A) Volcano plot of quantitative phospho-proteomic data of genetic sensitivity in H2009 clones (2 KP clones 401 and 2 KPL clones), two biological replicates each, N = 4 per genotype. Cells grown in 0.5 mM glucose for 6 402 hours. Phospho-peptides that pass statistical criteria (p-value < 0.05) are highlighted in black, red and blue, 403 peptides that do not satisfy this are colored grey. Phospho-peptides colored red satisfy a fold change > 1.5; colored blue, fold change < -1.5. TPI1 P-Ser21 peptide labeled in purple text. (B) Volcano plot of 404 405 quantitative phospho-proteomic data of genetic sensitivity in H2009 isogenic clones including clones with 406 transgenic expression of guide RNA resistant wildtype (WT) or kinase inactive (KI) LKB1 in LKB1-specific knockouts (sqLKB1-3.1 and sqLKB1-3.7) from Figure S1E. 4 biological replicates each. LKB1 Loss-of-407 408 function (LOF) group consisted of merging LKB1 knockout lines (KPL: sgLKB1-3.1 and sgLKB1-3.7) with 409 lines expressing guide RNA resistant LKB1 KI (KPL + LKB1 KI: sgLKB1-3.1 + LKB1 KI and sgLKB1-3.7 + 410 LKB1 KI); and compared to H2009 lines containing non-targeting guide RNA (KP: sgNT1.1 and sgNT1.2) 411 merged with LKB1 knockout lines expressing guide RNA resistant LKB1 WT (KPL + LKB1 WT: sgLKB1-3.1 412 + LKB1 WT and sgLKB1-3.7 + LKB1 WT) at the phospho-peptide level. Cells were grown in 0.5mM 413 glucose for 6 hours. Statistical criteria and color scheme same as for panel A. TPI1 P-Ser21 peptide 414 labeled in purple text. (C) Schematic showing metabolites (shaded in the orange box) chemically labeled to 415 create stable adducts. (D) In-situ chemical trapping metabolomics of hydroxylamine-labeled GAP and 416 DHAP in H2009 clones (KP: sgNT1.1 and sgNT1.2; KPL: sgLKB1-3.1 and sgLKB1-3.7) treated in culture for 417 6 hours with 11.1 mM or 0.5 mM respectively. Data presented are representative of three independent 418 biological experiments each containing three technical replicates and reported as the mean (-/+s.e.m.). Cell 419 number normalized across models 12 hours prior to assay and samples normalized to an exogenous 420 standard, d₃-serine. Statistical significance determined by two-tailed paired t-test. (E) Normalized ion 421 intensity of glycerol-3-phosphate from steady-state analysis of H2009 clones treated for 30 minutes with 422 11.1 or 0.5 mM glucose. Analysis conducted in H2009 isogenic clones (KP: sgNT1.1 and sgNT1.2; KPL: 423 sgLKB1-3.1 and sgLKB1-3.7) in biological triplicate and reported as the mean (-/+s.e.m.). Statistical 424 significance determined by two-tailed paired t-test. 425

Figure 3. LKB1 regulates the multimeric state of TPI1 in KP-mutant hLUAD but not in mLUAD cell lines due to an amino acid difference at position 21.

428 **(A)** Sequence alignment of TPI1 amino acid residues 16 to 26 across species, showing conservation of 429 Ser21 from H. sapiens to S. *Cerevisiae*, with cysteine at position 21 in mouse and rat Tpi1. Cartoon 430 comparing predicted side-chain chemistry, with oxidized cysteine and phosphorylated serine, is drawn 431 below. (B) Crystal structure of TPI1 homodimer (cyan and green respectively) with critical residues 432 highlighted in space-filling atoms. Serine 21 on the cyan monomer is highlighted in yellow. (C) Western 433 blot analysis of Blue Native PAGE of human isogenic clones derived from H358 and H441 cell lines. Cells 434 were grown under normal conditions (11.1 mM glucose). (D) Melting curve plot from Thermal Proteome 435 Profiling of unmodified and Serine 21 phosphorylated TPI1. Analysis conducted in H2009 isogenic clones expressing Cas9 and a non-targeting (sgNT1.1 and sgNT1.2) or LKB1-specific (sgLKB1-3.1 and 436 437 sqLKB13.7) guide RNA. (E) Western blot (Blue Native PAGE) of extracts from mLUAD cell lines. Cells 438 were cultured in either 11.1 mM or 0.5 mM glucose for 6 hours then treated with 1 mM H_2O_2 for 15 minutes. 439 (F) Western blot of proteins co-immunoprecipitated from extracts of H358 cells expressing Cas9 and a non-440 targeting (FH-GFP cell line) or TPI1-specific (all other cell lines) guide RNA and transgenic expression of 441 Flag-HA tagged GFP or guide RNA resistant TPI1 allelic variants using a polyclonal antibody against full-442 length TPI1. Cells were cultured in 11.1 mM glucose and treated with 250 µM Diamide or vehicle for 15 443 minutes prior to collection. (G) Western blot (Blue Native PAGE) of extracts of H358 cell lines used for coimmunoprecipitation in panel F. Cells were cultured in 11.1 mM glucose. 444

445

Figure 4. Salt Inducible Kinases phosphorylate human TPI1 in KP hLUAD cell lines.

447 (A) Cartoon depicting regulation of the AMPK-related (AMPKR) kinase family members by LKB1 and their 448 downstream substrates. (B) Bar graph of normalized ion abundance for the TPI1-derived ser-21 phospho-449 peptide from extracts of A549 cell-lines infected with an empty vector or a vector expressing wild type LKB1; 450 the indicated guide RNAs were used to inactivate members of the AMPKR subfamilies. Cell lines were 451 cultured in 11.1 mM glucose prior to analysis. Ion intensities were normalized to identified non-452 phosphorylated variants across conditions to control for protein expression and reported as the mean (-/+ 453 s.e.m.). (C) Volcano plot of quantitative proteomic data used to compare protein expression in clones of 454 H358 (2 KP clones and 2 KP SIK TKO clones, with 2 biological replicates of each). Cells were cultured in 455 11.1 mM glucose for 6 hours before lysis. Proteins that pass statistical criteria (p-value <0.05) are 456 highlighted in black, red and blue; those that do not satisfy this criterion are colored grey. Proteins 457 highlighted in red satisfy the fold change threshold (>1.5) after triple deletion of SIK1.2.3. Proteins 458 highlighted in blue satisfy the fold change threshold of < -1.5) for a decrease after SIK1,2,3 triple deletion. 459 KRAS is labeled in purple text. (D) Bar graph of normalized ion abundance for the TPI1-derived, ser-21 460 phospho-peptide in extracts of isogenic H358 cell-lines containing a non-targeting control (sgNT1.3) or SIK1 461 specific (sgSIK1.3) guide RNA and additional control (NT1) SIK1 (sgSIK1) or dual SIK2 and SIK3 462 (sgSIK2/3) guide RNAs. Ion intensities were normalized against identified non-phosphorylated variant 463 across conditions. Cell lines were cultured in 11.1 mM glucose prior to lysis, analyzed in biological 464 triplicate, and reported as the mean (-/+ s.e.m.).

465

466

467

468

469 470

471

472

473

474

475 476

477

478

479

480

481






Figure 1









1,3-BPG


Lower Glycolysis

TPI1

D








glycerol-3-phosphate - 11.1 mM Glucose

NH,OH

Stable

Adducts

Trap



glycerol-3-phosphate - 0.5 mM Glucose






Figure 2



Native-PAGE

Figure 3



483 Supplemental Figure Legends

484

505

Figure S1. Differential co-occurrence and effects of *KRAS*, *TP53* and *LKB1* mutations on human and mouse LUADs


487 (A) MSK Impact oncoprint of co-occurrence of KRAS, TP53 and LKB1 mutations in human lung 488 adenocarcinomas, with Fisher's exact test of statistical likelihood of co-occurrence of LKB1 and TP53 489 mutations in a LUAD with a KRAS mutant or wildtype background. (C) 3D spheroid growth in Matrigel of 490 isogenic clones of the H358 cell line labeled with a tdTomato fluorescent reporter and expressing CAS9 and 491 non-targeting controls (sgNT1.4 and sgNT1.6) or LKB1-specific (sgLKB1-2.1 and sgLKB1-3.2) guide RNAs. 492 5,000 cells were seeded into Matrigel and grown for 10 days in media changed every 24 hours. Images 493 taken on EVOS fluorescence microscope under 4x magnification and filter to resolve tdTomato signal 494 intensity and brightfield. (D) 3D spheroid growth in Matrigel of GEMM-derived mLUAD cell lines containing 495 transgenic lentiviral expression of GFP under control of a CMV promoter. 5,000 cells were seeded into 496 Matrigel and assay was conducted for 10 days in culture media changed every 24 hours. Images taken on 497 EVOS fluorescence microscope under 10x magnification and filter to resolve GFP signal intensity and 498 brightfield. (E) Western blot analysis of H2009 (KRAS; TP53) isogenic clones (KP: sgNT1.1 and sgNT1.2; 499 KPL: sqLKB1-3.1 and sqLKB1-3.7) and lines with additional transgenic expression of guide RNA resistant 500 LKB1 wildtype (WT) (sgLKB1-3.1 + LKB1 WT and sgLKB1-3.7 + LKB1 WT) or LKB1 kinase inactive (KI) 501 (sqLKB1-3.1 + LKB1 KI and sqLKB1-3.7 LKB1 KI) and treated with 11.1 mM or 0.5 mM glucose for 6 hours 502 as indicated. Restoration of AMPK signaling in LKB1 WT lines in response to 0.5 mM glucose validated by 503 blotting for P-AMPK Thr172 and downstream substrates (P-ACC S79, P-ULK1 S555, P-Raptor S792). 504 Similar results observed in three independent experiments.

506Figure S2. Phosphorylation of human TPI1 is LKB1-dependent and regulates triose phosphate507levels.


508 (A and B) Volcano plots for comparison of phospho-peptides enriched from lysates of H358 and H441 509 isogenic clones respectively with and without LKB1 [2 KP clones (H358: sgNT1.4 and sgNT1.6; H441: 510 sqNT1.2 and sqNT1.4) and 2 KPL clones (H358: sqLKB1-2.1 and sqLKB1-3.2. H441: sqLKB1-2.2 and 511 sqLKB1-3.3) with 2 biological replicates for each cell line]. Cells were grown in 0.5 mM glucose for 6 hours 512 before lysis. Phospho-peptides that pass statistical criteria (p-value <0.05) are highlighted in black, red and 513 blue, peptides that do not satisfy this criterion are colored grey. Phospho-peptides highlighted in red satisfy 514 a fold-change threshold (>1.5) upon LKB1 deletion: those highlighted in blue satisfy the fold change 515 threshold (<-1.5) upon LKB1 deletion. Phospho-peptides referenced in the text (SIK3, CRTC3, PRKAB1 516 and PRKAB2) are labeled in purple text. (C) Volcano plot for comparison of quantitative phospho-proteomic 517 data of genetic sensitivity in mLUAD cell-lines, 634T (KP) and Lkb1-t2 (KPL) in biological triplicate for each 518 condition. Analysis conducted on cells treated with 0.5mM glucose for 6 hours in culture. Statistical criteria 519 and color scheme same as for panel A and B. (D) Average ion intensity of the H2009 (KRAS;TP53) 520 isogenic clones (KP: sqNT1.1 and sqNT1.2; KPL: sqLKB1-3.1 and sqLKB1-3.7) and lines with additional 521 transgenic expression of guide RNA resistant LKB1 wildtype (WT) (sgLKB1-3.1 + LKB1 WT and sgLKB1-522 3.7 + LKB1 WT) or LKB1 kinase inactive (KI) (sgLKB1-3.1 + LKB1 KI and sgLKB1-3.7 LKB1 KI) for the 523 phospho-peptide containing Serine 21 of TPI1 from the experiments from which the volcano plot in Figure 524 2B was derived. Bar graph depicts each genotype individually and shows restoration of TPI1 525 phosphorylation in KPL lines expressing transgenic WT LKB1 but not KI LKB1. Ion intensities were 526 normalized to identified non-phosphorylated variant across conditions to control for protein expression; the 527 relevant phospho-peptide was observed 3 times in each biological replicate. (E) Schematic showing 528 hydroxylamine chemical labeling and conversion of the triose phosphates; GAP and DHAP to their oxime 529 derivatives. (F) In-situ chemical trapping metabolomics of hydroxylamine-labeled GAP and DHAP in H2009 530 clones (KP: sqNT1.1 and sqNT1.2; KPL: sqLKB1-3.1 and sqLKB1-3.7) and additionally lines with transgenic 531 expression of guide RNA resistant LKB1 wildtype (WT) (sgLKB1-3.1 + LKB1 WT and sgLKB1-3.7 + LKB1 532 WT) or LKB1 kinase inactive (KI) (sgLKB1-3.1 + LKB1 KI and sgLKB1-3.7 LKB1 KI) and treated in culture 533 for 6 hours with 11.1 mM or 0.5 mM respectively. Data presented are representative of three independent 534 biological experiments each containing two technical replicates and reported as the mean ratio (GAP-535 trap/DHAP-trap) (-/+s.e.m.). Cell number normalized across models 12 hours prior to assay and samples 536 normalized to an exogenous standard, d_3 -serine.


537 Figure S3. Members of the salt Inducible kinase family phosphorylate TPI1.

(A) Bar graph of normalized ion abundance for the TPI1-derived Ser-21 phospho-peptide in extracts of A549 cell-lines expressing an empty vector or wild type LKB1 and guide RNAs specifically targeting combinations of members of the Salt Inducible Kinase family. Cell lines were cultured in 11.1 mM glucose. (B) Graphs depicting the mean mRNA level (+ s.d.) of the Salt Inducible Kinases in the indicated isogenic clones of H2009 (left) and H358 (right). (C) Western blots showing abundance of SIK1, SIK2 and SIK3 in H358 isogenic clones after exposure to the indicated guide RNAs for members of the SIK family. H358 isogenic clones expressing Cas9 and containing non-targeting control (sgNT1.3 and sgNT1.4) or SIK1 specific (sqSIK1.3 and sqSIK1.4) guide RNA and additional non-targeting (NT1), SIK1 (sqSIK1) or dual SIK2 and SIK3 (sgSIK2/3) guide RNAs.



H2009





P-TPI1 Ser21 1500000 Average lon Intensity 1000000 0 J.

500000

0

sgCTRL sgLKB1

3 4 5

H441 clones

Phospho


- sgLKB1+LKB1 wt 0
- sgLKB1+LKB1 ki


F

GAP-trap / DHAP-trap

0.0

59CTRL





SOLVEN LENNE SOLVEN LENN

11.1 mM glucose D.5 mM glucose



bioRxiv preprint doi: https://doi.org/10.1101/2021.10.01.452764; this version posted October 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the thor/funder. All rights reserved. No reuse allowed without permission. TPI1 P-Ser21 Α 4000000 H2009 clones Normalized Ion Intensity H358 clones 8 8 Relative mRNA level **Relative mRNA level** 3000000 6 6 SIK1 A549+EV 2000000 4 4 SIK2 A549+LKB1 SIK3 2 2 1000000 ₀∐ UÌÌ lîn ΠŇ لل ہ Fahrle Baken Sahren 32 SONTI? SOLIES SOLARIA. HAN'S SSHALL 59MT1.1 59MT1.A 0 T LYBIX 295HUR 7 3-3-4 - 1- 2-54 HAR3 7 , 1, KB1 * 55, KC 1×81^{* 5551×1} 7 1,481 * 55143 С sgSIK1.4 NT1.3 sgSIK1.3 NT1.4 \$ \$ \$ \$ } } } -595213 \$952¹³ 99° 505 500 S.S.S. Jr' JAN . "AI" 411 SIK1 SIK2 SIK3 Actin

H358

587 Methods

588

589 No statistical methods were used to predetermine sample size. Data were visualized and statistical

analyses performed using Prism 9 software (Graph Pad) or R statistical package. P < 0.05 was considered
 statistically significant. P values for paired comparisons between two groups with comparable variance were

592 calculated by two-tailed Student's t-test. 593

594 **Reagents**

595 Media and sera were purchased from Life Technologies and R&D Systems respectively. All other reagents 596 were from Sigma-Aldrich unless otherwise noted. 597

598 Cell lines

All cell lines (A549, H358, H441, H2009, 634T and HEK293T) were purchased from ATCC or kindly provided by Kwok-Kin Wong at NYU Langone Medical Center (634T and Lkb1-t2). Cells were maintained in RPMI 1640 medium (Life Technologies: 11879020) supplemented with glucose concentrations as indicated (Life Technologies: A2494001) except for HEK293T cells, which were propagated in DMEM with sodium pyruvate and L-glutamine (Corning). All media supplemented with 10% FBS, 100 units/ml of penicillin and 100 μ g/ml streptomycin and grown at 37°C in a 5% CO₂, humidified incubator. All cell lines were confirmed to be mycoplasma-free using the MycoAlert mycoplasma detection kit (Lonza: LT07-218)

to be mycoplasma-free using the MycoAlert mycoplasma detection kit (Lonza: LT07-218).

607 CRISPR/Cas9 reagents, plasmids

The control and LKB1-KO lines were generated by infecting the cell lines with lentivirus generated from the LentiCRISPRv2 plasmid (Addgene: 52961). The control and TPI1-KO or SIK-KO lines were generated by

609 LentiCRISPRV2 plasmid (Addgene: 52961). The control and TPI1-KO or SIK-KO lines were generated b 610 infecting the Cas9-expressing lines (LentiCRISPRv2) with lentivirus generated from the LRT2B plasmid

611 (Addgene: 110854). The sgRNA sequences are as follows: sgNT1, CCAATACGGACCGGATTGCT;

612 sgLKB1-2, TGTATAACACATCCACCAGC; sgLKB1-3, TGCACAAGGACATCAAGCCG; sgSAFE,

613 GGTTGGATAAGGCTTAGAAA; sgTPI1-3, GAAGTACACGAGAAGCTCCG; sgTPI1-4,

614 GGAAGCCATCCACATCAGGC; sgSlK1, ATGGTCGTGACAGTACTCCA; sgSlK2,

615 GCACCGGATCACCAAGACGG; sgSIK3, GTGCTTGCAGATCTGCTCCA. The TPI1 alleles were

616 synthesized by Twist Biosciences and cloned into pHAGE-CMV-N-Flag-HA-IRES-Puro-DEST via Gateway 617 cloning.

618

619 Lentivirus production, transduction and single-cell cloning

Lentivirus was generated by transfecting the target plasmid with the packaging plasmids pMD2.G
(Addgene: 12259) and psPAX2 (Addgene: 12260) into 293T cells using Lipofectamine 3000 (Invitrogen:
L3000015). Media was changed 6 hours after transfection, and then the viral supernatant was collected at
24 and 48h post-transfection. Transduction was conducted in 6 well format on 1 x 10⁵ cells and cells plated

624 in suspension into viral supernatant containing 8 μ g/ml Polybrene (Santa Cruz Biotechnology: SC-134220)

- and incubated overnight (16h). Viral supernatant aspirated and fresh culturing media added to transduced
 cells for recovery for 24h. Puromycin (Life Technologies: A1113803) was supplemented into media 48h
 post-transduction for relevant plasmids (LentiCRISPRv2 and pHAGE-CMV-N-Flag-HA-IRES-PURO) at a
- 628 concentration of 2 µg/ml and selection conducted for 72h. Blasticidin (Invivogen: ANT-BL-1) was 629 supplemented into media 48h post-transduction for relevant plasmid (LRT2B) at a concentration of 10 µg/ml
- and selection conducted for 5 days. Following selection, single cell cloning was conducted by serial dilution
- and plating into a 96 well plate, and cells were maintained under relevant selection criteria during the
 cloning process. Clones that grow out from single cells were expanded and validation of knockout
 conducted by western-blot or gPCR as indicated.
- 634

635 LUAD clinical data set analysis.

Human LUAD (hLUAD) datasets (TCGA and MSKCC) were downloaded from cBioPortal and KRAS, TP53,
 and LKB1 mutational and copy number status were assessed. Samples were divided into KRAS-mutant and
 KRAS-wild-type cohorts for further analysis. Using the R statistical software package, a Fisher's exact test

639 was performed on each cohort to determine the odds of TP53 and LKB1 mutations co-occurring.

641 Mice and xenografts.

Animal procedures were performed with the approval of the Weill Cornell Medicine IACUC. Tumor volume was not allowed to exceed 1000 mm³ in any experiment. Prior to implantation, cells were re-suspended in PBS and mixed 1:1 with Matrigel (Corning, 356231). Cells were then injected subcutaneously into single flanks of 6-week-old athymic mice (Envigo). Caliper measurements were performed weekly to monitor tumor growth. For the H358 LKB1-KO clones, 1 x 10⁶ cells were injected per flank; for the murine lung tumor lines (634T and Lkb1-t2) 1 x 10⁴ cells were injected per flank.

648 649 Western blotting

650 Protein lysates were prepared in CST lysis buffer (Cell Signaling Technology: 9803) supplemented with 651 cOmplete mini EDTA free protease inhibitor (Roche: 04693159001) and guantified using the BCA protein 652 assay (Thermo Scientific, 23225). Lysates prepared at a concentration of 1 mg/ml and supplemented with 653 4x Laemmli Sample Buffer (Bio-Rad: 1610747) supplemented with fresh 2-mercaptoethanol (Sigma: 654 M3148). Proteins were separated on self-cast Tris-glycine polyacrylamide gels, transferred to Polyscreen 655 PVDF membranes (Perkin Elmer: NEF1002), and probed with Cell Signaling Technology antibodies used at 656 1:1000 in 5% BSA (Sigma: A4503) in TBS-T: P-ACC Ser79 (#3661), ACC (#3662), P-Raptor Ser792 657 (#2083), Raptor (#2280), P-AMPKa Thr172 (#2535), AMPK a1/2 (#2532), LKB1 (#3047), P-ULK1 Ser555 658 (#5869), ULK1 (#8054) and SIK2 (6919). Antibodies from Abcam used at concentrations indicated in 5% 659 BSA in TBS-T against β-actin (ab6276, 1:20,000), TPI1 (ab96696, 1:3,000) and P-SIK1 Thr182 + P-SIK2 Thr175 + P-SIK3 Thr163 (ab199474, 1:1000). Antibody from Novus Biologicals was used at 1:20,000 in 5% 660 661 BSA in TBS-T against SIK3 (NBP2-47278). Antibodies from Sigma-Aldrich against Flag epitope tag (F7425, 1:5,000) and (F3165, 1:1000) were used at indicated concentrations in 5% BSA in TBS-T. 662 663 Secondary antibodies from Millipore against Rabbit (AP132PMI) and Mouse (AP124PMI) primary antibodies 664 were resuspended per manufacturer's instructions and used at 1:10.000 in 5% non-fat dried milk in TBS-T. 665 Western blots were then developed in the dark room on an autoradiograph following incubation with home-666 made ECL.

667

668 Sn-glycerol-3-phosphate steady state analysis metabolite extraction

669 Cells were cultured in medium reconstituted from glucose-free RPMI 1640 medium (Life Technologies: 670 11879020) supplemented with 11.1 or 0.5 mM glucose and 10% dialyzed FBS. The day prior to treatment 671 and collection cells were lifted and counted and 2 x 10⁶ cells were plated in a 10cm culture dish. Cells were 672 given a medium change 1 h before the addition of growth medium. Cells were rinsed twice with PBS before 673 the addition of tracing medium. The time of addition of tracer medium was designated time 0. Metabolites 674 were extracted at 30 minutes post addition as indicated in text.

675

676 Aqueous metabolite extraction and liquid chromatography–mass spectrometry (LC–MS) analysis

677 Cells were washed twice with PBS, and twice with LC-MS grade H₂O. Five hundred µl of 80% methanol at 678 -80 °C was added to guench metabolic reactions and the cells were collected by scraping. The lysate was 679 then transferred to a fresh 2.0 ml Eppendorf tube pre-chilled on dry-ice and an additional 500 µl of 80% 680 methanol was added to the original plate and scraped again. The second lysate was added to the first and 681 incubated on dry ice for 20 minutes with intermittent vortexing then centrifuged at 16,000g for 10 min to 682 allow cellular debris to be pelleted. The aqueous volume was then transferred to a clean, fresh pre-chilled 683 2.0 ml Eppendorf tube and dried under vacuum in a speedvac and stored at -80°C. Dried sample pellets 684 were resuspended in HPLC-grade water (20 µl) and centrifuged at 20,000 g for 5 min to remove insoluble 685 material. Following centrifugation, 16 µl of supernatant was transferred to virgin polypropylene auto sampler 686 vials, capped and placed on dry ice. Supernatants (5 µl) were injected and analyzed using a hybrid 6500 QTRAP triple quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC HPLC system 687 688 (Shimadzu) via selected reaction monitoring (MRM). ESI voltage was +4900V in positive ion mode with a 689 dwell time of 3 ms per SRM transition. Approximately 10–14 data points were acquired per detected 690 metabolite. Samples were delivered to the mass spectrometer via hydrophilic interaction chromatography 691 (HILIC) using a 4.6 mm i.d. x 10 cm Amide XBridge column (Waters) at 400 µl/min. Gradients were run 692 starting from 85% buffer B (HPLC grade acetonitrile) to 42% B from 0 to 5 min; 42% B to 0% B from 5 to 16 693 min; 0% B was held from 16 to 24 min; 0% B to 85% B from 24 to 25 min; 85% B was held for 7 min to re-694 equilibrate the column. Buffer A was comprised of 20 mM ammonium hydroxide/20 mM ammonium acetate

(pH = 9.0) in 95:5 water:acetonitrile. Peak areas from the total ion current for each metabolite SRM
transition were integrated using MultiQuant v3.0 software (AB/SCIEX). Tubes containing cellular debris was
retained to determine protein concentration for data normalization. Briefly pellet was resuspended by
addition of 600 µl of sodium hydroxide and boiled at 90 °C for 30 minutes with intermittent vortexing.
Resolubilized pellets were allowed to come to room temperature, and protein quantified using the DC
protein assay (Bio-Rad: 5000111). Derived metabolite data was normalized to protein concentration and
median ion intensity per injection across the dataset.

702

703 In situ hydroxylamine trapping in live cells

704 Two 15 cm dishes per condition were plated with 9 x 10⁶ cells 24 hr prior to treatment. Plated cells were washed twice with PBS then grown in RPMI 1640 media containing 11.1 mM or 0.5 mM alucose as 705 706 indicated for 6 hr. Cells were then washed twice with PBS and 3 ml of PBS containing protease inhibitors 707 was added to the plate and cells were scraped. Cell homogenate was transferred to a 15ml conical tube 708 and centrifuged at 1,400 x g for 3 minutes to pellet cells. Cellular pellets were resuspended in 300 µl ice 709 cold 80% Methanol and transferred to a 1.5 ml Eppendorf tube. Chemical labeling of live cells was 710 achieved by adding 10 µl of hydroxylamine solution (Sigma: 467804, ~15M solution) and incubated for 10 711 minutes with gently vortexing intermittently. Following a 10 minute incubation, the suspended cells were 712 lysed with a probe sonicator set to 30% amperage pulse (1:1 pulse; pause 16 seconds total). Lysed cellular 713 homogenates were then centrifuged at 20,000 x g for 10 minutes at 4 °C. Clarified supernatant was 714 transferred to a fresh 1.5 ml Eppendorf tube and dried under Nitrogen gas flow until all solvent was 715 evaporated. Dried pellets were then stored at -80 °C until ready for analysis. Dried metabolites were 716 resuspended in 100 μ L of an 80:20 mixture of MeOH/H₂O and an internal deuterated standard, 10 nmol d_3 -717 serine, was added to the dried metabolome solution for quantification and sample normalization. 718

719 Targeted LC-MS/MS for hydroxylamine trapping

Resuspended metabolites were separated by hydrophilic interaction chromatography with a Gemini 720 721 reverse-phase C18 column (50 mm x 4.6 mm with 5 µm diameter particles) from Phenomenex together with 722 precolumn (C18, 3.5 mm, 2 mm X 20 mm). Mobile phase A was composed of 100% H₂O (10 mM 723 tributylamine aqueous solution, adjusted to pH 4.95 with 15 mM acetic acid), and mobile phase B was 724 composed of 100% Methanol. Using a multi-step gradient with buffer A and B: 0-5 min, 95% A; 5-15 min, 725 95-90% A; 15-22 min, 90-85% A; 22-26 min, 10% A, and maintained for 4 min; 30-33 min, 95% A, and 726 maintained for 7 min. The flow rate was 0.2 ml/min for 0-15 min and 30-40 min. and 0.3 ml/min for 15-30 727 min. Targeted MS/MS analysis was performed on an Agilent triple guadrupole LC-MS/MS instrument 728 (Agilent Technologies 6460 QQQ). The capillary voltage was set to 4.0 kV. The drying gas temperature 729 was 350°C, the drying gas flow rate was 10 L/min, and the nebulizer pressure was 45 psi. Relative 730 metabolite abundance was quantified by integrated peak area for the given MRM-transition. Data 731 presented are representative of three independent biological experiments each containing three technical 732 replicates for a given condition.

733

734 **Proteomics and phospho-proteomic sample preparation**

735 Protein lysates were prepared in CST lysis buffer (Cell Signaling Technology: 9803) supplemented with 736 cOmplete mini EDTA free protease inhibitor (Roche: 04693159001) and quantified using the BCA protein 737 assay (Thermo Scientific, 23225). Following quantification, 100 µg of each protein lysate was moved into a 738 clean 1.5 mL tube. Following distribution of protein, each tube was brought to a final volume of 300 µL by 739 addition of PBS, followed by precipitation with trichloroacetic acid (TCA) (Sigma) to a final concentration of 740 25%, vigorously vortexed and incubated on ice overnight. TCA precipitates were centrifuged at 21,130 x g 741 for 30 minutes at 4°C, washed twice in 500 μ L of ice-cold acetone, and centrifuged at 21,130 x g for 10 742 minutes after each wash. Following precipitation and washes, pellets were allowed to completely dry at 743 room temperature. Dry pellets were re-suspended in 100 µL of 100 mM TEAB, 0.5% SDS and reduced with 744 9.5 mM tris-carboxyethyl phosphine (TCEP) for 60 minutes at 55°C. Following reduction of disulfide bonds 745 with TCEP, the denatured protein mix was centrifuged at 21,130 x α for 5 minutes then alkylated with 4.5 746 mM iodoacetamide (IA) for 30 minutes in the dark at room temperature. After reduction and alkylation of 747 disulfide bonds, the denatured protein mixture was precipitated out of solution by addition of 600 µL of ice-748 cold acetone and placed in the -20°C freezer overnight. The following day precipitated proteins were

centrifuged at 8,000 *x g* for 10 minutes to pellet precipitated protein. Following centrifugation supernatant was decanted off and pellets were allowed to air-dry at room temperature. Once dry, protein pellets were reconstituted in 100 μ L 100 mM TEAB and CaCl₂ was supplemented to a final concentration of 1 mM, 2 μ g of sequencing grade Trypsin (Promega) was added, and reactions were placed in the dark on a thermal mixer (Eppendorf) set to 37°C and shaking at 850 r.p.m. for 16 hours.

755 Thermal Proteomic Profiling

754

756 Cells were lifted using TrypLE Express (Thermo Fisher Scientific - GIBCO) and neutralized following 5-757 minute incubation using complete media (RPMI + 10% FBS penicillin/streptomycin) and centrifuged at 1100 758 r.p.m. for 4 minutes. The cell pellet was reconstituted in 10 mL PBS containing protease and phosphatase 759 inhibitors (Roche) and centrifuged again at 1100 RPM for 4 minutes. Following centrifugation, the cell pellet 760 was resuspended in 1 mL PBS with inhibitors and distributed into thin-wall PCR tubes at 100 µL of cell 761 suspension in each tube. Thermal denaturation was performed as previously described, and the resulting 762 cellular suspension was transferred to clean 1.5 mL microcentrifuge tubes and PCR tubes were additionally 763 rinsed with 30 µL of PBS with inhibitors to ensure complete transfer of cellular suspension. Cellular 764 suspension was next snap frozen in liquid nitrogen for 1 minute followed by thawing and re-equilibration 765 back to room temperature. This freeze-thaw cycle was repeated 2 additional times and the soluble fraction 766 of each lysate was generated by centrifugation at 21,130 x α for 30 minutes at 4°C. Supernatants were 767 transferred to clean 1.5 mL microcentrifuge tubes, and protein was guantified in the supernatant for 768 temperatures 37°C and 41°C by micro-BCA assay (Thermo Fisher Scientific - Pierce). Following 769 guantification, the average of the two lowest temperatures was taken and the volume equivalent to 30 µg of 770 protein in the lowest temperature was moved from each temperature fraction into a clean 1.5 mL tube. 771 Following distribution of protein, each tube was brought to a final volume of 300 µL by addition of PBS with 772 inhibitors, followed by precipitation with trichloroacetic acid (TCA) (Sigma) to a final concentration of 25%, 773 vigorously vortexed and incubated on ice overnight. TCA precipitates were centrifuged at 21,130 x g for 30 774 minutes at 4°C, washed twice in 500 μ L of ice-cold acetone, and centrifuged at 21,130 x g for 10 minutes 775 after each wash. Following precipitation and washes, pellets were allowed to completely dry at room 776 temperature. Dry pellets were re-suspended in 100 µL of 100 mM TEAB, 0.5% SDS and reduced with 9.5 777 mM tris-carboxyethyl phosphine (TCEP) for 60 minutes at 55°C. Following reduction of disulfide bonds with 778 TCEP, the denatured protein mix was centrifuged at 21,130 x g for 5 minutes then alkylated with 4.5 mM 779 iodoacetamide (IA) for 30 minutes in the dark at room temperature. After reduction and alkylation of 780 disulfide bonds, the denatured protein mixture was precipitated out of solution by addition of 600 µL of ice-781 cold acetone and placed in the -20°C freezer overnight. The following day precipitated proteins were 782 centrifuged at 8,000 x g for 10 minutes to pellet precipitated protein. Following centrifugation supernatant 783 was decanted off and pellets were allowed to air-dry at room temperature. Once dry, protein pellets were 784 reconstituted in 100 µL 100 mM TEAB and CaCl₂ was supplemented to a final concentration of 1 mM, 1 µg 785 of sequencing grade Trypsin (Promega) was added, and reactions were placed in the dark on a thermal 786 mixer (Eppendorf) set to 37°C and shaking at 850 r.p.m. for 16 hours. The next day, digested samples were 787 centrifuged at 21,130 x q for 10 minutes and proceeded to TMT labeling of digested samples.

788

789 TMT Labeling, Fractionation, and Phosphopeptide Enrichment

790 TMT labeling was performed generally as per manufacturer's protocol. Briefly, each TMT tag was re-791 suspended in 164 µL anhydrous acetonitrile with intermittent vortexing for 10 minutes. Following 792 resuspension, 41 µL was added to corresponding temperatures (TMT-126 = 37°C; four separate aliguots of 793 each temperature for subsequent desalting and fractionation) and labeling reaction was allowed to proceed 794 for 1 hour at room temperature. Reactions were quenched by addition of 8 µL of 5% hydroxylamine in 100 795 mM TEAB and incubated for 15 minutes. Labeled temperature fractions were pooled, desalted on 1cc/50 796 mg C18 SepPAK columns (Waters # WAT054955) on a vacuum manifold and desalted peptides were dried 797 down in a speedvac. Dried peptides were reconstituted in 300 μ L of 0.1% TFA in H₂O, high-pH reverse 798 phase spin-columns (Thermo fisher scientific - Pierce) were equilibrated, and samples fractionated per 799 manufacturer's instructions into 8 fractions, 2 washes and a flow-through fraction (11 total). Separate 800 samples from the same fractions were then combined and dried. Peptide fractions were reconstituted in 200 801 µL of 5% acetonitrile, 0.1% TFA in water, and 10 µL was removed for bulk HTP analysis. The remaining 802 fractionated labeled peptides dried and re-dissolved in 40% acetonitrile, 6% TFA in water before

803 phosphopeptide enrichment with Titansphere 5 µm TiO₂ beads (GL Sciences). Titansphere TiO2 beads (GL 804 Sciences) were reconstituted in buffer containing 80% acetonitrile, 6% TFA, and 2,5-dihydroxybenzoic acid 805 (20 mg/mL) and rotated for 15 min at 25°C. Equal amount of beads slurry (~5:1 beads-to-peptide ratio 806 based on concentration of peptides in 37°C aliguot) was added to each temperature aliguot of reconstituted 807 peptides and rotated for 20 mins 25°C. Beads were then washed twice with higher percentage of 808 acetonitrile (10% and 40%) in 6% TFA and supernatant was removed by centrifugation at 500 x g for 2 min. 809 Washed beads were then added to self-packed stage tip with C8 SPE (Sigma Aldrich) and washed once 810 more with 60% acetonitrile in 6% TFA. Phosphopeptides were first eluted with 5% NH₄OH, then 10% 811 NH₄OH, 25% acetonitrile, and dried with speedvac. Dried phosphopeptides were reconstituted in 5% 812 acetonitrile, 1% TFA, desalted with self-packed stage tip with C18 SPE (Sigma Aldrich), and dried with 813 speedvac once more. The final processed phosphopeptides were reconstituted in 5% acetonitrile, 0.1% 814 TFA in water for LC-MS³ analysis.

815

816 LC-MS³ Analysis and Data Acquisition

High-pH reverse-phase fractions were run on a 4-hour instrument method with an effective linear gradient of 817 818 180 minutes from 5% to 25% mobile phase B with the following mobile phases: A: 0.1% formic acid in H_2O_1 , 819 B: 80% acetonitrile/0.1% formic acid in water on a 50 cm Acclaim PepMap RSLC C18 column (Thermo 820 Fisher Scientific #164942) operated by a Dionex ultimate 3000 RSLC nano pump with column heating at 821 50°C connected to an Orbitrap Fusion Lumos. Briefly, the instrument method was a data-dependent 822 analysis and cycle time set to 3 seconds, total. Each cycle consisted of one full-scan mass spectrum (400-823 1500 m/z) at a resolution of 120,000, RF Lens: 60%, maximum injection time of 100 ms followed by data-824 dependent MS/MS spectra with precursor selection determined by the following parameters: AGC Target of 825 4.0e⁵, maximum injection time of 100 ms, monoisotopic peak determination: peptide, charge state inclusion: 826 2-7, dynamic exclusion 10 sec with an intensity threshold filter: 5.0e³. Data-dependent MS/MS spectra were 827 generated by isolating in the quadrupole with an isolation window of 0.4 m/z with CID activation and 828 corresponding collision energy of 35%, CID activation time of 10 ms, activation Q of 0.25, detector type Ion 829 Trap in Turbo mode, AGC target of 1.0e4 and maximum injection time of 120 ms. Data-dependent multi-830 notch MS³ was done in synchronous precursor selection mode (SPS, multi-notch MS³) with the following 831 settings: Precursor selection Range; Mass Range 400-1200, Precursor Ion Exclusion Properties m/z Low: 832 18 High: 5, Isobaric Tag Loss Exclusion Properties: TMT. Number of SPS precursors was set to 10 and 833 data-dependent MS³ was detected in the Orbitrap (60.000 resolution, scan range 120-500) with an isolation 834 window of 2 m/z HCD activation type with collision energy of 55%, AGC target of 1.2e5 and a maximum 835 injection time of 150 ms. Raw files were parsed into MS1, MS2 and MS3 spectra using RawConverter. 836

837 Proteomic, phospho-proteomic and Thermal Profiling Data Analysis

838 Data generated were searched using the ProLuCID algorithm in the Integrated Proteomics Pipeline (IP2) 839 software platform. Human and Mouse proteome data were searched using concatenated target/decoy 840 UniProt databases. Basic searches were performed with the following search parameters: HCD 841 fragmentation method; monoisotopic precursor ions; high resolution mode (3 isotopic peaks); precursor 842 mass range 600-6,000 and initial fragment tolerance at 600 p.p.m.; enzyme cleavage specificity at C-843 terminal lysine and arginine residues with 3 missed cleavage sites permitted; static modification of 844 +57.02146 on cysteine (carboxyamidomethylation), +229.1629 on N-terminal and lysine for TMT-10-plex 845 tag; 4 total differential modification sites per peptide, including oxidized methionine (+15.9949), and 846 phosphorylation (+79,9663) on serine, threenine, and tyrosine (only for phospho-enriched samples); primary 847 scoring type by XCorr and secondary by Zscore; minimum peptide length of six residues with a candidate 848 peptide threshold of 500. A minimum of one peptide per protein and half-tryptic peptide specificity were 849 required. Starting statistics were performed with a Δ mass cutoff = 10 p.p.m. with modstat, and trypstat 850 settings. False-discovery rates of protein (pfp) were set to 1% (for unenriched datasets) or peptide (sfp) set 851 to 1% (for phospho-proteomics datasets). TMT quantification was performed using the isobaric labeling 10-852 plex labeling algorithm, with a mass tolerance of 5.0 p.p.m. or less. Reporter ions 126.127726, 127.124761, 853 127.131081. 128.128116. 128.134436. 129.131417. 129.13779. 130.134825. 130.141145. and 131.13838 854 were used for relative quantification.

856 **References**:

857 1 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 70, 7-30, doi:10.3322/caac.21590 (2020).

Pavlova, N. N. & Thompson, C. B. The Emerging Hallmarks of Cancer Metabolism. *Cell Metab* 23, 27-47, doi:10.1016/j.cmet.2015.12.006 (2016).

- 8613Chen, P. H. *et al.* Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. *Mol Cell* 76, 838-862851 e835, doi:10.1016/j.molcel.2019.08.028 (2019).
- 8665Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical867sequencing of 10,000 patients. Nat Med 23, 703-713, doi:10.1038/nm.4333 (2017).
- Eichner, L. J. *et al.* Genetic Analysis Reveals AMPK Is Required to Support Tumor Growth in Murine
 Kras-Dependent Lung Cancer Models. *Cell Metab* 29, 285-302 e287, doi:10.1016/j.cmet.2018.10.005
 (2019).
- 8717Hollstein, P. E. et al. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive872Effects of LKB1 in NSCLC. Cancer Discov 9, 1606-1627, doi:10.1158/2159-8290.CD-18-1261 (2019).
- 8738Liu, Y. et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in874LKB1-mutant lung cancer. Cancer Discov 3, 870-879, doi:10.1158/2159-8290.CD-13-0015 (2013).
- 8759Rogers, Z. N. *et al.* Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression876in mice. Nature Genetics **50**, 483-486, doi:10.1038/s41588-018-0083-2 (2018).
- 877 10 Orozco, J. M. *et al.* Dihydroxyacetone phosphate signals glucose availability to mTORC1. *Nature* 878 *Metabolism* 2, 893-901, doi:10.1038/s42255-020-0250-5 (2020).
- Anastasiou, D. *et al.* Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to
 Cellular Antioxidant Responses. *Science* 334, 1278-1283, doi:10.1126/science.1211485 (2011).
- 88112Cheung, E. C. *et al.* Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of882Pancreatic Cancer. *Cancer Cell* **37**, 168-182.e164, doi:10.1016/j.ccell.2019.12.012 (2020).
- 88313DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and
tumorigenesis. Nature 475, 106-109, doi:10.1038/nature10189 (2011).
- Chang, J. W., Lee, G., Coukos, J. S. & Moellering, R. E. Profiling Reactive Metabolites via Chemical Trapping and Targeted Mass Spectrometry. *Analytical Chemistry* 88, 6658-6661, doi:10.1021/acs.analchem.6b02009 (2016).
- Roland, B. P. *et al.* Triosephosphate isomerase I170V alters catalytic site, enhances stability and induces pathology in a Drosophila model of TPI deficiency. *Biochim Biophys Acta* 1852, 61-69, doi:10.1016/j.bbadis.2014.10.010 (2015).
- 89116Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science892**346**, 1255784, doi:10.1126/science.1255784 (2014).
- Huang, J. X. *et al.* High throughput discovery of functional protein modifications by Hotspot Thermal
 Profiling. *Nature Methods* 16, 894-901, doi:10.1038/s41592-019-0499-3 (2019).
- Faubert, B. *et al.* Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer
 cells via HIF-1α. *Proceedings of the National Academy of Sciences* **111**, 2554-2559,
 doi:10.1073/pnas.1312570111 (2014).
- 89819Xu, H. G. et al. LKB1 reduces ROS-mediated cell damage via activation of p38. Oncogene 34, 3848-8993859, doi:10.1038/onc.2014.315 (2015).
- 90020Li, F. et al. LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer901Plasticity and Therapeutic Response.Cancer Cell27, 698-711,902doi:https://doi.org/10.1016/j.ccell.2015.04.001 (2015).
- 90321Kim, J. et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer904cells. Nature 546, 168-172, doi:10.1038/nature22359 (2017).
- 90522Shackelford, D. B. & Shaw, R. J. The LKB1–AMPK pathway: metabolism and growth control in tumour906suppression. Nature Reviews Cancer 9, 563-575, doi:10.1038/nrc2676 (2009).
- 90723Sun, Z., Jiang, Q., Li, J. & Guo, J. The potent roles of salt-inducible kinases (SIKs) in metabolic908homeostasis and tumorigenesis. Signal Transduction and Targeted Therapy 5, 150,909doi:10.1038/s41392-020-00265-w (2020).

- 910 24 Sakamoto, K., Bultot, L. & Göransson, O. The Salt-Inducible Kinases: Emerging Metabolic Regulators.
 911 *Trends in Endocrinology & Metabolism* 29, 827-840, doi:10.1016/j.tem.2018.09.007 (2018).
- Berggreen, C., Henriksson, E., Jones, H. A., Morrice, N. & Göransson, O. cAMP-elevation mediated
 by β-adrenergic stimulation inhibits salt-inducible kinase (SIK) 3 activity in adipocytes. *Cellular Signalling* 24, 1863-1871, doi:https://doi.org/10.1016/j.cellsig.2012.05.001 (2012).
- 915 26 Itoh, Y. *et al.* Salt-inducible Kinase 3 Signaling Is Important for the Gluconeogenic Programs in Mouse
 916 Hepatocytes *. *Journal of Biological Chemistry* 290, 17879-17893, doi:10.1074/jbc.M115.640821
 917 (2015).
- 91827DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific919antigens underlies cancer immunoediting. *Nature* **482**, 405-409, doi:10.1038/nature10803 (2012).
- 920 28 Ngo, B. *et al.* Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH 921 Inhibition. *Cancer Discovery* **10**, 1352-1373, doi:10.1158/2159-8290.Cd-19-1228 (2020).
- Murray, C. W. *et al.* An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation.
 Cancer Discov 9, 1590-1605, doi:10.1158/2159-8290.CD-18-1237 (2019).
- 92430Garcia, D. & Shaw, R. J. AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic925Balance. Molecular Cell 66, 789-800, doi:10.1016/j.molcel.2017.05.032 (2017).